$BLAC
Bellevue Life Sciences Acquisition Corp.

2023 Q2 Form 10-Q Financial Statement

#000089843223000326 Filed on May 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $280.3K $278.1K $0.00
YoY Change 28267.71%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $280.3K $278.1K $0.00
YoY Change 28267.71%
Operating Profit
YoY Change
Interest Expense $810.0K $420.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $530.0K $140.0K $0.00
YoY Change
Income Tax $228.6K $29.32K
% Of Pretax Income 43.13% 20.94%
Net Earnings $301.5K $110.3K -$126.00
YoY Change -30612.55% -87643.65%
Net Earnings / Revenue
Basic Earnings Per Share $0.03 $0.02
Diluted Earnings Per Share $0.03 $0.02 $0.00
COMMON SHARES
Basic Shares Outstanding 9.055M shares 9.055M shares
Diluted Shares Outstanding 9.055M shares 5.231M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $350.0K
YoY Change -100.0%
Cash & Equivalents $1.181K $348.8K $16.39K
Short-Term Investments
Other Short-Term Assets $60.00K $80.00K
YoY Change
Inventory
Prepaid Expenses $57.80K $81.07K
Receivables
Other Receivables
Total Short-Term Assets $58.98K $429.9K
YoY Change -15.75%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $71.44M $70.63M
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $71.44M $70.63M
YoY Change 7115.71%
TOTAL ASSETS
Total Short-Term Assets $58.98K $429.9K
Total Long-Term Assets $71.44M $70.63M
Total Assets $71.49M $71.06M
YoY Change 6644.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $270.0K $390.0K
YoY Change
Accrued Expenses $0.00 $0.00
YoY Change -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $541.4K $403.4K
YoY Change -48.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $541.4K $403.4K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.611M $2.473M
YoY Change 146.36%
SHAREHOLDERS EQUITY
Retained Earnings -$2.095M -$1.830M
YoY Change
Common Stock $216.00 $216.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.095M -$1.830M -$2.246K
YoY Change
Total Liabilities & Shareholders Equity $71.49M $71.06M
YoY Change 6644.76%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $301.5K $110.3K -$126.00
YoY Change -30612.55% -87643.65%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$350.0K -$48.43K -$126.00
YoY Change 3400.0% 38333.33%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$70.21M
YoY Change
Cash From Investing Activities $0.00 -$70.21M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $70.48M $11.76K
YoY Change -100.0% 599170.7%
NET CHANGE
Cash From Operating Activities -350.0K -$48.43K -$126.00
Cash From Investing Activities 0.000 -$70.21M
Cash From Financing Activities 0.000 $70.48M $11.76K
Net Change In Cash -350.0K $224.3K $11.64K
YoY Change -600.0% 1827.81%
FREE CASH FLOW
Cash From Operating Activities -$350.0K -$48.43K -$126.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
BELLEVUE LIFE SCIENCES ACQUISITION CORP.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41390
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-5052822
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
10900 NE 4th Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bellevue
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98004
CY2023Q1 dei City Area Code
CityAreaCode
425
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
635-7700
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9055000 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
348802 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124501 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
81073 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
429875 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124501 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1101353 usd
CY2023Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
70625228 usd
CY2023Q1 us-gaap Assets
Assets
71055103 usd
CY2022Q4 us-gaap Assets
Assets
1225854 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
386432 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
34000 usd
CY2022Q4 blac Accrued Offering Costs Current
AccruedOfferingCostsCurrent
12362 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
1200000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
403432 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1263362 usd
CY2023Q1 blac Deferred Underwriting Commissions
DeferredUnderwritingCommissions
2070000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2473432 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1263362 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2155000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
216 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24827 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1830452 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62508 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1830236 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71055103 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1225854 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
278102 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
126 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-278102 usd
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-126 usd
CY2023Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
417728 usd
CY2023Q1 us-gaap Other Income
OtherIncome
417728 usd
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
139626 usd
CY2022 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-126 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29321 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
110305 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-126 usd
CY2023Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5231461 shares
CY2022 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1500000 shares
CY2023Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.02
CY2022 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-37508 usd
CY2023Q1 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1236527 usd
CY2023Q1 blac Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-7439560 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
110305 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1830236 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-2120 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-126 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-2246 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-110305 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
126 usd
CY2023Q1 us-gaap Interest Income Interest Earning Asset Increase Decrease
InterestIncomeInterestEarningAssetIncreaseDecrease
417728 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
81073 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
340070 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48426 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-126 usd
CY2023Q1 us-gaap Assets Held In Trust
AssetsHeldInTrust
70207500 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70207500 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59670000 usd
CY2023Q1 blac Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
-1447273 usd
CY2022Q1 blac Deferred Underwriting Fee Payable
DeferredUnderwritingFeePayable
-78239 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70480227 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11761 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
224301 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
11635 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124501 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4757 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348802 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16392 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2070000 usd
CY2023Q1 blac Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1 pure
CY2023Q1 us-gaap Share Price
SharePrice
10
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9000000 usd
CY2023Q1 blac Percentage Of Trust Account Required For Business Combination
PercentageOfTrustAccountRequiredForBusinessCombination
0.80 pure
CY2023Q1 blac Threshold Percentage Of Outstanding Voting Securities Of Target To Be Acquired By Post Transaction Company To Complete Business Combination
ThresholdPercentageOfOutstandingVotingSecuritiesOfTargetToBeAcquiredByPostTransactionCompanyToCompleteBusinessCombination
0.50 pure
CY2023Q1 us-gaap Common Stock Held In Trust
CommonStockHeldInTrust
70207500 usd
CY2023Q1 blac Net Tangible Assets
NetTangibleAssets
5000001 usd
CY2023Q1 blac Redemption Limit Percentage
RedemptionLimitPercentage
0.15 pure
CY2023Q1 blac Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1 pure
CY2023Q1 blac Period To Consummate Business Combination
PeriodToConsummateBusinessCombination
P9M
CY2023Q1 blac Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000 usd
CY2023Q1 us-gaap Cash
Cash
348802 usd
CY2023Q1 us-gaap Debt Current
DebtCurrent
26443 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="color: #231F20; font-family: 'Times New Roman', serif; font-weight: bold;">Use of Estimates</div><div><br/> </div><div style="text-align: justify; text-indent: 36pt; color: #231F20; font-family: 'Times New Roman', serif;">The preparation of unaudited condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of unaudited condensed financial statements and the reported amounts of expenses during the reporting periods.</div><div><br/> </div><div style="text-align: justify; text-indent: 36pt; color: #231F20; font-family: 'Times New Roman', serif;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effects of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</div>
CY2023Q1 us-gaap Cash
Cash
348802 usd
CY2022Q4 us-gaap Cash
Cash
124501 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="color: #231F20; font-family: 'Times New Roman', serif; font-weight: bold;">Concentration of Credit Risk</div><div><br/> </div><div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', serif;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</div>
CY2023Q1 blac Common Stock Shares Excluded From Calculation Of Net Income Loss Per Share
CommonStockSharesExcludedFromCalculationOfNetIncomeLossPerShare
7330000 shares
CY2023Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6900000 shares
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
0 shares
CY2023Q1 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
7500 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
17000 usd
CY2023Q1 blac Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
2 pure
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
69000000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
1236527 usd
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
4791126 usd
CY2023Q1 blac Accretion For Common Stock To Redemption Value
AccretionForCommonStockToRedemptionValue
-7439560 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155000 shares
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Common stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders.
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7330000 shares
CY2023Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
70625228 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001840425

Files In Submission

Name View Source Status
0000898432-23-000326-index-headers.html Edgar Link pending
0000898432-23-000326-index.html Edgar Link pending
0000898432-23-000326.txt Edgar Link pending
0000898432-23-000326-xbrl.zip Edgar Link pending
blac-20230331.htm Edgar Link pending
blac-20230331.xsd Edgar Link pending
exh31-1.htm Edgar Link pending
exh31-2.htm Edgar Link pending
exh32-1.htm Edgar Link pending
exh32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
blac-20230331_cal.xml Edgar Link unprocessable
blac-20230331_lab.xml Edgar Link unprocessable
blac-20230331_pre.xml Edgar Link unprocessable
blac-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
blac-20230331_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending